Condition

Chlamydial infection

Clinical trials and treatment information for Chlamydial infection

152.2M

People Affected

Active Trials

130M

New Cases/Year

1,033

Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

Doxycycline

97% Effectiveness• 95% Confidence• 70% Safety• 17 trials• 1M participants

HIGH EvidenceExcellent ValueDose: 100mg orally twice daily for 7 days

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

1 week for cure

Duration

7 days

Response Rate

97%

Remission Rate

97%

Number Needed to Treat (NNT)

1.03

Common Side Effects:

Nausea: 15%

Diarrhea: 10%

Photosensitivity: 5%

Esophageal irritation: 3%

Annual Cost of Care

Drug Cost

$15

Monitoring

$600

Side Effects

$10

Total Annual

$625

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.08

Cost per Remission

$25.77

Cost per Responder

$25.77

Treatment Outcomes

Primary Outcomes

Microbiological Eradication (C. trachomatis NAAT)100% positive Nucleic Acid Amplification Test (NAAT)

-95% (-95 percentage points in positivity)

Urethral Symptom Severity Score (e.g., based on validated questionnaire)Score of 6/10 (moderate to severe symptoms)

-80% (-4.8 points)

Cervical/Vaginal Symptom Severity Score (e.g., based on validated questionnaire)Score of 6/10 (moderate to severe symptoms)

-80% (-4.8 points)

Secondary Benefits

Incidence of Pelvic Inflammatory Disease (PID) in WomenAnnual incidence rate of 10% in untreated women with C. trachomatis

-90% (-9 percentage points in annual incidence)

Pelvic Pain Intensity (Visual Analog Scale)Score of 5/10 (moderate pain)

-70% (-3.5 points)

Health-Related Quality of Life (e.g., SF-36 Physical Component Summary)Score of 45 (out of 100, population norm is 50)

+11.1% (+5 points)

Common Side Effects

Nausea

+15%

Diarrhea

+10%

Photosensitivity

+5%

Clinical Trial Phases:

Phase 4

Azithromycin

97% Effectiveness• 95% Confidence• 70% Safety• 47 trials• 1.5M participants

HIGH EvidenceExcellent ValueDose: 1g orally in a single dose

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Single dose for cure, symptoms improve in days

Duration

Single dose

Response Rate

97%

Remission Rate

97%

Number Needed to Treat (NNT)

1.03

Common Side Effects:

Nausea: 10%

Diarrhea: 8%

Abdominal pain: 5%

Vomiting: 3%

Annual Cost of Care

Drug Cost

$15

Monitoring

$600

Side Effects

Total Annual

$620

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.08

Cost per Remission

$20.62

Cost per Responder

$20.62

Treatment Outcomes

Primary Outcomes

Microbiological Cure Rate (Genital C. trachomatis)100% C. trachomatis positive (at infection sites)

+97% (97% of patients achieved microbiological cure)

Resolution of Genital Symptoms (e.g., discharge, dysuria)Presence of symptomatic urethritis/cervicitis

+85% (85% of patients reported full symptom resolution)

Microbiological Cure Rate (Rectal C. trachomatis)100% C. trachomatis positive (rectal site)

+92% (92% of patients achieved microbiological cure)

Secondary Benefits

Reduction in Pelvic Inflammatory Disease (PID) IncidenceEstimated 10-30% risk of PID in untreated women

-90% (Risk reduced from 10-30% to <5%)

Reduction in C. trachomatis Sexual TransmissionHigh risk of onward transmission (e.g., 50-70% for partners of untreated)

-98% (Near elimination of onward transmission risk)

Resolution of Urethritis/Epididymitis Symptoms in MenPresence of symptomatic urethritis or epididymitis

+88% (88% of men reported full symptom resolution)

Common Side Effects

Nausea

+10%

Diarrhea

+8%

Abdominal pain

+5%

Clinical Trial Phases:

Phase 4

Levofloxacin

96% Effectiveness• 90% Confidence• 65% Safety• 300 trials• 200K participants

MODERATE EvidenceGood ValueDose: 500mg orally once daily for 7 days

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

1 week for cure

Duration

7 days

Response Rate

96%

Remission Rate

96%

Number Needed to Treat (NNT)

1.04

Common Side Effects:

Nausea: 10%

Diarrhea: 8%

Headache: 5%

Tendinitis/Tendon rupture: 0.1%

Peripheral neuropathy: 0.05%

Annual Cost of Care

Drug Cost

$30

Monitoring

$600

Side Effects

$20

Total Annual

$650

Cost-Effectiveness

GOOD

QALYs Gained

0.07

Cost per Remission

$52.08

Cost per Responder

$52.08

Treatment Outcomes

Efficacy Outcomes

Overall Effectiveness

+96%

Response Rate

+96%

Remission Rate

+96%

Common Side Effects

Nausea

+10%

Diarrhea

+8%

Headache

+5%

Clinical Trial Phases:

Phase 4

Erythromycin

85% Effectiveness• 85% Confidence• 68% Safety• 39 trials• 100K participants

MODERATE EvidenceModerate ValueDose: 500mg orally four times daily for 7 days or 250mg orally four times daily for 14 days

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

7-14 days for cure

Duration

7-14 days

Response Rate

85%

Remission Rate

85%

Number Needed to Treat (NNT)

1.18

Common Side Effects:

Nausea: 25%

Vomiting: 20%

Abdominal pain: 15%

Diarrhea: 15%

Annual Cost of Care

Drug Cost

$30

Monitoring

$600

Side Effects

$30

Total Annual

$660

Cost-Effectiveness

MODERATE

QALYs Gained

0.06

Cost per Remission

$70.59

Cost per Responder

$70.59

Treatment Outcomes

Primary Outcomes

Microbiological Cure (Genital Chlamydia trachomatis)Infection detected by NAAT (100% of treated patients)

-88% (88% achieve negative NAAT at test-of-cure)

Resolution of Urogenital Symptoms (e.g., dysuria, discharge)Presence of symptoms (e.g., discharge, dysuria)

-82% (82% report complete resolution of symptoms)

Resolution of Neonatal Chlamydial ConjunctivitisClinical signs of conjunctivitis present

-92% (92% clinical and microbiological resolution)

Secondary Benefits

Reduction in Risk of Pelvic Inflammatory Disease (PID)Estimated 10-30% risk of PID in untreated women

-90% (Reduction in PID incidence from ~15% to <2%)

Reduction in Risk of EpididymitisEstimated 5-10% risk of epididymitis in untreated men

-90% (Reduction in epididymitis incidence from ~7% to <1%)

Reduction in Onward Chlamydia TransmissionInfectious state (high transmission risk)

-100% (Cessation of infectiousness)

Common Side Effects

Nausea

+25%

Vomiting

+20%

Abdominal pain

+15%

Clinical Trial Phases:

Phase 4